Startseite>>Peptides>>Bremelanotide Acetate (PT-141 Acetate)

Bremelanotide Acetate (PT-141 Acetate) (Synonyms: Bremelanotide Acetate)

Katalog-Nr.GC34002

Bremelanotidacetat (PT-141-Acetat) (PT-141-Acetat), ein synthetisches Peptidanalogon von ⋱-MSH, ist ein Agonist an Melanocortinrezeptoren, einschließlich MC3R und MC4R, zur Behandlung von sexueller Dysfunktion.

Products are for research use only. Not for human use. We do not sell to patients.

Bremelanotide Acetate (PT-141 Acetate) Chemische Struktur

Cas No.: 1607799-13-2

Größe Preis Lagerbestand Menge
10mM (in 1mL DMSO)
55,00 $
Auf Lager
10mg
46,00 $
Auf Lager
50mg
138,00 $
Auf Lager

Tel:(909) 407-4943 Email: sales@glpbio.com

Kundenbewertungen

Basiert auf Kundenrezensionen.

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Description Chemical Properties Product Documents Related Products

Bremelanotide Acetate is a melanocortin agonist.IC50 value:Target: melanocortinin vivo: Bremelanotide is a novel drug candidate for the treatment of male and female sexual dysfunction. Bremelanotide has shown promise in effectively treating erectile dysfunction (ED) without the cardiovascular effects found in ED drugs currently available. Bremelanotide works through a mechanism of action involving the central nervous system rather than directly on the vascular system. As a result, it may offer significant safety and efficacy benefits over currently available products.

Bewertungen

Review for Bremelanotide Acetate (PT-141 Acetate)

Average Rating: 5 ★★★★★ (Based on Reviews and 38 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for Bremelanotide Acetate (PT-141 Acetate)

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.